• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»hematologic malignancies

TScan Therapeutics strengthens heme pipeline with dual IND clearances

By Soujanya Ravi on February 27, 2026   Pharma & Biotech  

TScan Therapeutics strengthens heme pipeline with dual IND clearances

TScan Therapeutics advances its ALLOHA trial and expands CD45-targeted TCR-T coverage. Discover what this means for relapse prevention.

Is deceased donor marrow a viable backup graft? First human data from Ossium says yes

By Pallavi Madhiraju on January 24, 2026   Pharma & Biotech  

Is deceased donor marrow a viable backup graft? First human data from Ossium says yes

Ossium unveils early data on cryopreserved cadaveric marrow in transplants. Find out what this could mean for urgent graft availability.

Can epcoritamab reshape salvage DLBCL care? Genmab’s Phase 3 data brings regulatory momentum

By Pallavi Madhiraju on January 17, 2026   Pharma & Biotech  

Can epcoritamab reshape salvage DLBCL care? Genmab’s Phase 3 data brings regulatory momentum

Genmab’s epcoritamab improved PFS in a Phase 3 DLBCL trial. Find out how this could reshape bispecific monotherapy in aggressive B-cell lymphoma care.

Recent Posts

  • Can Zai Lab’s ZL-1503 turn dual-pathway itch control into a real atopic dermatitis advantage?
  • IntoDNA unveils sSTRIDE-NER and sSTRIDE-PARP1 at AACR 2026, can functional DNA repair assays reshape precision oncology?
  • Soley Therapeutics shows early tumor selectivity for STX-6398, but can CKAP2 modulation scale?
  • Akamis Bio AACR 2026 update: what early NG-350A data could mean for organ preservation
  • AACR 2026: SAGA Diagnostics pushes Pathlight MRD deeper into metastatic breast and ovarian cancer
  • Agenus AACR 2026 data show immune reprogramming signal in PD-1 refractory gastroesophageal cancer
  • AACR 2026: Can Zai Lab’s zocilurtatug pelitecan change the treatment picture for small cell lung cancer brain metastases?
  • How JANX014 expands Janux Therapeutics’ tumor-activated platform strategy in prostate cancer immunotherapy
  • What Medicus Pharma Ltd.’s SkinJect application signals for Hedgehog pathway-driven cancers
  • Why Bioxodes’ adaptive trial strategy could accelerate approval timelines in stroke therapeutics
  • What Kura Oncology’s latest data reveals about resistance biology in kidney cancer
  • Can Fate Therapeutics, Inc. solve the conditioning chemotherapy problem in CAR T?
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes